Marlborough medical device company Boston Scientific announced Wednesday that it has entered into an agreement to acquire the global surgical business of Lumenis LTD.
The agreement with an affiliate of Baring Private Equity Asia (BPEA) would see Boston Scientific pay $1.07 billion for the private company that develops and commercializes energy-based medical solutions.
Among Lumenis’ surgical business is premier laser systems, fibers and accessories used for urology and otolaryngology procedures, such as kidney stone treatments. Lumenis sales for 2021 are expected to be approximately $200 million.
Boston Scientific has had a relationship with Israel-based Lumenis for more than 20 years and currently sells the Lumenis urology laser portfolio in the U.S. and Japan through a distribution arrangement. Upon completion of the acquisition, Boston Scientific will sell these lasers and fibers – as well as the otolaryngology laser portfolio – to all geographies, including high-growth regions like China.
BPEA will retain ownership of the Lumenis global aesthetics and ophthalmology businesses. The acquisition is expected to close in the second half of 2021.
